We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI-Powered Test Predicts Risk of Developing Esophageal Cancer in Patients with Barrett’s Esophagus

By LabMedica International staff writers
Posted on 16 May 2023
Print article
Image: TissueCypher is a risk-stratification test to predict future development of esophageal cancer in patients with BE (Photo courtesy of Castle Biosciences)
Image: TissueCypher is a risk-stratification test to predict future development of esophageal cancer in patients with BE (Photo courtesy of Castle Biosciences)

Barrett's esophagus (BE) is a serious consequence of gastroesophageal reflux disease (GERD) and presents a risk for the onset of esophageal cancer, one of the fastest-increasing cancers in terms of incidence in the U.S., exhibiting a less than 20% five-year survival rate. Effective interventions such as ablation therapy are typically applied to patients with higher grades of BE to prevent its progression to esophageal cancer. However, a substantial number of BE patients are classified with lower grades of BE or as non-dysplastic. Despite population-based predictions indicating a low cancer development probability for these lower-grade patients, they constitute the majority of patients who ultimately progress to esophageal cancer. This discrepancy indicates a significant clinical need for personalized, biologically based risk-stratification information to ensure a better alignment between progression risk and the application of effective interventions.

Castle Biosciences’ (Pittsburgh, PA, USA) TissueCypher Barrett’s Esophagus test is the world’s first precision medicine test that predicts the future development of esophageal cancer in patients with BE. The TissueCypher test provides medical professionals with vital information regarding an individual patient's risk of progression to esophageal cancer based on advanced analysis of biopsy samples, thus enabling better-informed, risk-aligned patient management. Its clinical effectiveness has been validated through nine peer-reviewed publications involving BE progressor patients across leading clinical centers worldwide.

The TissueCypher test is designed for use in patients with endoscopic biopsy-confirmed BE that is graded as non-dysplastic, indefinite for dysplasia, or low-grade dysplasia. Precise and accurate prediction of progression from BE to high-grade dysplasia or esophageal adenocarcinoma is crucial, given the rapidly growing incidence of esophageal cancer. Since esophageal adenocarcinoma is highly fatal once diagnosed, early detection and advanced warning provided by the TissueCypher test in BE patients can offer crucial clinical decision support for physicians treating these patients. Castle Biosciences was selected as the winner of the “Best Use of Artificial Intelligence in Healthcare” award in the seventh annual MedTech Breakthrough Awards program for its innovative TissueCypher Barrett’s Esophagus test.

“Most cancer diagnoses and associated risk-stratification estimates are currently made by pathologists viewing tissue on glass slides via light microscopy. This approach is limited in its ability to evaluate multiple biomarkers and cell types within the tumor system and predict future development of cancer,” said James Johnson, managing director, MedTech Breakthrough. “TissueCypher utilizes artificial intelligence to predict the risk of developing esophageal cancer – one of the world’s most deadly cancers. Congratulations to the Castle team on winning the ‘Best Use of Artificial Intelligence in Healthcare’ award in 2023.”

Related Links:
Castle Biosciences 

Flocked Swab
HydraFlock and PurFlock Ultra
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
Semi-Automatic Coagulation Analyzer
Clot 2B
Incubation & Imaging System
BD KiestraReadA

Print article


Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more


view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more


view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more


view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more


view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more


view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more


view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.